耐药结核病治疗方法,这是第三阶段平台试验的案例
Tom A Yates1, Samara Barnes2, Martin Dedicoat3
1Institute of Health Informatics, University College London, 222 Euston Road, LondonNW1 2DA, England.
Bulletin of the World Health Organization
|September 2, 2024
概括
大多数针对耐药结核病的III期试验过慢,可能会隐藏关键数据. 需要一个协作,适应性平台试验,以获得新的结核病治疗方法的更快,更可靠的结果.
科学领域:
- 传染性疾病 传染性疾病
- 临床试验 临床试验
- 结核病研究 结核病研究
背景情况:
- 针对耐药结核病 (DR-TB) 的III期试验面临挑战,其终点不够强大,持续时间长,往往超过十年.
- 目前的复合终点可能会掩盖治疗失败和复发率的关键差异,尽管新的DR-TB疗法显然有效.
- 对新型抗结核药物快速出现的耐药性突显出迫切需要新的,更短,更安全,更耐受的治疗方案,包括对抗抗达奎林耐药结核有效的治疗方案.
研究的目的:
- 倡导从传统的A疗法与B疗法试验转向针对耐药结核病的大规模,协作性III期平台试验.
- 强调现代适应性平台设计的潜力,以加快为DR-TB治疗方案获取可靠的疗效和安全数据.
- 强调研究人员,患者,资助者和监管机构之间合作的必要性,以开发高效和有效的DR-TB临床试验.
主要方法:
- 讨论目前针对耐药结核病的第三阶段试验设计的局限性.
- 建议过渡到一个单一的大型III期平台试验结构.
- 建议采用适应性平台试验设计,以提高效率.
主要成果:
- 目前的试验结构往往不足或过长,阻碍了对耐药结核病治疗的及时评估.
- 复合终点可能不准确地反映真正的治疗疗效,掩盖了重要的临床结果,如失败和复发.
- 新兴的耐药性需要对耐药结核病的临床试验方法进行范式转变.
结论:
- 使用适应性设计的大型,协作性III期平台试验对于加速开发有效的耐药结核病治疗方法至关重要.
- 与传统的试验格式相比,这样的平台试验将提供相对有效性和安全性的更可靠估计.
- 有效的发展需要所有参与耐药结核病研究和治疗的利益相关者之间的密切合作.
更多相关视频
相关概念视频
01:28Pulmonary Tuberculosis V
174
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
174
01:26Pulmonary Tuberculosis IV
134
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
134
01:31Pulmonary Tuberculosis III
316
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
316
01:11Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
01:28Pulmonary Tuberculosis II
215
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
215
01:29Pulmonary Tuberculosis I
227
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
227